ondasdechoque.org
PT-BR

Trapezius pain: shockwaves versus injection and TENS · Randomized trial · 2012

Does shockwave help neck and shoulder muscle pain compared with injections?

In this trial, pain in the muscle across the top of the shoulder fell from about 7 to about 2 out of 10 after three shockwave sessions, one a week. With trigger-point injections plus TENS (mild electrical stimulation), it fell to about 3. Sore spots became less tender to pressure with shockwave.

Both eased pain
people with neck and shoulder muscle pain
30
sessions, one a week
3
week after the last session: final check
1

Good to know: All were hospital inpatients.

Jeon JH, Jung YJ, Lee JY, et al. Ann Rehabil Med, 2012 · Read the paper ↗

How this study worked

Shockwave15 peopleInjections + TENS15 people
People were assigned to the groups by lot. Each dot is one person.

What happened

Neck and shoulder muscle pain

0–10 pain scale · start and 1 week after the third session

Start1 week after the last session

Pain fell from about 7 to about 2 out of 10 with shockwave, and from about 7 to about 3 with injections plus TENS. Both groups improved a lot over three weeks.
Show the numbers
GroupPeopleStart1 week after the last session
Shockwave156.861.86
Injections + TENS157.22.8

The treatment

Shockwave

Shockwave, once a week for 3 weeks

ShockwavesThe paper doesn’t say whether radial or focused
Sessions
3, one a week
Pulses
1,500 per session · 240 shocks a minute, aimed at the sore spots
Strength
0.10mJ/mm²
Numbing
Not mentioned
Device
EvoTron RFL0300

Compared with: Trigger-point injections once a week plus TENS (mild electrical stimulation) 20 minutes a day, five days a week, for three weeks

Settings are what each study used, not a prescription.

Who took part

30 hospital patients (22 men, 8 women; average age 41–45) with pain in the muscle across the top of the shoulder and back of the neck.

Shockwave15 people
Injections + TENS15 people

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Hospital patients with posterior neck/shoulder pain and trapezius myofascial pain diagnosed on examination in 2011; 22 men and 8 women. Mean age was 40.86 in ESWT and 45.00 in control.

ESWT15randomized

Source reports this participant group.

Injection plus TENS15randomized

Source reports this participant group.

Pain intensity2 reported outcomes
01
One week after first treatment

Pain intensity

VAS points

means
GroupnBaselineFollow-up
ESWT156.86 (SD 0.9)2.86 (SD 0.9)
Injection plus TENS157.2 (SD 1.3)4.6 (SD 0.55)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 6.86 = 48/7, 1.86 = 13/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (group F = 9.940 with p = 0.010). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed.

02
One week after third treatment

Pain intensity

VAS points

means
GroupnBaselineFollow-up
ESWT156.86 (SD 0.9)1.86 (SD 0.69)
Injection plus TENS157.2 (SD 1.3)2.8 (SD 0.84)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 6.86 = 48/7, 1.86 = 13/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (group F = 9.940 with p = 0.010). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed.

Algometry2 reported outcomes
03
One week after first treatment

Pain threshold

Algometry lb/cm²

means
GroupnBaselineFollow-up
ESWT156.86 (SD 1.35)11.43 (SD 0.27)
Injection plus TENS156.2 (SD 1.92)8.8 (SD 0.48)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 11.43 = 80/7, 12.57 = 88/7) and every control mean a multiple of 1/5, and its printed group and time F and p values fit 12 patients in total (group F = 5.237 with p = 0.045). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed. Table 3 prints the group×time test as F = 4.550 with p = 0.001 (the text repeats p = 0.001); an F of 4.550 on 2 numerator degrees of freedom corresponds to p of roughly 0.01–0.04, so the F or the p value is misprinted.

04
One week after third treatment

Pain threshold

Algometry lb/cm²

means
GroupnBaselineFollow-up
ESWT156.86 (SD 1.35)12.57 (SD 0.72)
Injection plus TENS156.2 (SD 1.92)9.6 (SD 2.19)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 11.43 = 80/7, 12.57 = 88/7) and every control mean a multiple of 1/5, and its printed group and time F and p values fit 12 patients in total (group F = 5.237 with p = 0.045). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed. Table 3 prints the group×time test as F = 4.550 with p = 0.001 (the text repeats p = 0.001); an F of 4.550 on 2 numerator degrees of freedom corresponds to p of roughly 0.01–0.04, so the F or the p value is misprinted.

McGill pain2 reported outcomes
05
One week after first treatment

McGill pain

McGill points

means
GroupnBaselineFollow-up
ESWT1531 (SD 8.41)15.71 (SD 8.67)
Injection plus TENS1524.4 (SD 6.02)16.8 (SD 5.17)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 15.71 = 110/7, 8.71 = 61/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (group×time F = 4.150 with p = 0.031). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed.

06
One week after third treatment

McGill pain

McGill points

means
GroupnBaselineFollow-up
ESWT1531 (SD 8.41)8.71 (SD 2.81)
Injection plus TENS1524.4 (SD 6.02)12 (SD 3.39)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 15.71 = 110/7, 8.71 = 61/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (group×time F = 4.150 with p = 0.031). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed.

Pain rating2 reported outcomes
07
One week after first treatment

Pain rating

PRS points

means
GroupnBaselineFollow-up
ESWT1526.57 (SD 18.54)7.86 (SD 5.52)
Injection plus TENS1525.2 (SD 7.95)11.2 (SD 2.59)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 7.86 = 55/7, 4.57 = 32/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (time F = 10.864 with p = 0.004, Wilks' lambda). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed.

08
One week after third treatment

Pain rating

PRS points

means
GroupnBaselineFollow-up
ESWT1526.57 (SD 18.54)4.57 (SD 3.6)
Injection plus TENS1525.2 (SD 7.95)8.6 (SD 0.89)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 7.86 = 55/7, 4.57 = 32/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (time F = 10.864 with p = 0.004, Wilks' lambda). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed.

Total ROM2 reported outcomes
09
One week after first treatment

Total neck motion

Total ROM degrees

means
GroupnBaselineFollow-up
ESWT15267.86 (SD 17.29)297.86 (SD 12.86)
Injection plus TENS15263 (SD 31.35)290 (SD 20.62)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 267.86 = 1,875/7, 302.14 = 2,115/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (group F = 0.379 with p = 0.552). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed. One other Table 5 pair (left-rotation group, F = 0.496 with p = 0.186) fits no sample size. Table 2 prints the control baseline as 263.00 ± 31.34; Table 5 prints ± 31.35 (stored).

10
One week after third treatment

Total neck motion

Total ROM degrees

means
GroupnBaselineFollow-up
ESWT15267.86 (SD 17.29)302.14 (SD 9.94)
Injection plus TENS15263 (SD 31.35)298 (SD 7.58)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed. Extractor's arithmetic check (not reported by the authors): every ESWT mean in this table is an exact multiple of 1/7 (e.g. 267.86 = 1,875/7, 302.14 = 2,115/7) and every control mean a multiple of 1/5, and the printed F and p values for this outcome fit 12 patients in total (group F = 0.379 with p = 0.552). These results are therefore consistent with about 7 ESWT and 5 control patients, not the 15 per group the paper reports; the paper does not explain this. Values and n are kept as printed. One other Table 5 pair (left-rotation group, F = 0.496 with p = 0.186) fits no sample size. Table 2 prints the control baseline as 263.00 ± 31.34; Table 5 prints ± 31.35 (stored).

Global response and motion1 reported outcome
11
Final assessment, one week after the third treatment (neck-motion tests span all three assessments)

Global response and motion

Qualitative finding

Roles/Maudsley: excellent/good 6/9 with ESWT; excellent/good/acceptable 3/9/3 with control (p=.233). Trigger-point response excellent/good 10/5 versus 6/9 (p=.272). All neck-motion group and interaction tests were nonsignificant.

Analysis details and source

Qualitative extraction preserves the source scope.

How treatment was delivered
ESWT protocol

EvoTron RFL0300 electrohydraulic low-energy ESWT, 1,500 shocks per session, 0.10 mJ/mm² and 240 shocks/minute; three weekly sessions (4,500 total shocks), targeting twitch/referred-pain sites.

Comparator

Trigger-point injections once weekly for three weeks plus TENS 20 minutes/day, five times weekly for three weeks. Injection drug and dose are not reported sufficiently for replication.

HARMS & TOLERABILITY

The paper discusses expected safety of low-energy ESWT but does not provide systematic event counts for this trial. Absence of a harm table is not evidence of zero adverse events.

LIMITS OF THE ANALYSIS

Hospital sample and brief observation, unclear allocation safeguards, multiple outcomes and incomplete comparator details. The distinction between group main effect and interaction is essential: authors overinterpret VAS superiority despite a null interaction. No dedicated funding/conflict statement was found in the supplied article.

Extractor's arithmetic check (not reported by the authors): the continuous results in Tables 2–6 fit about 12 analysed patients rather than 30. Every ESWT mean is an exact multiple of 1/7 and every control mean a multiple of 1/5; Table 6's means for 'n=22' men and 'n=8' women are multiples of 1/9 and 1/3; and the printed F and p values fit 12 patients in total. The categorical counts (Table 1, Roles–Maudsley, final response) do cover 15 per group. Two printed F and p pairs do not match each other at any sample size: pain-threshold group×time (F = 4.550, p = 0.001; that F gives p of roughly 0.01–0.04) and left-rotation group (F = 0.496, p = 0.186). The paper explains none of this.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Hospital sample and brief observation, unclear allocation safeguards, multiple outcomes and incomplete comparator details. The distinction between group main effect and interaction is essential: authors overinterpret VAS superiority despite a null interaction. No dedicated funding/conflict statement was found in the supplied article.
  • Extractor's arithmetic check (not reported by the authors): the continuous results in Tables 2–6 fit about 12 analysed patients rather than 30. Every ESWT mean is an exact multiple of 1/7 and every control mean a multiple of 1/5; Table 6's means for 'n=22' men and 'n=8' women are multiples of 1/9 and 1/3; and the printed F and p values fit 12 patients in total. The categorical counts (Table 1, Roles–Maudsley, final response) do cover 15 per group. Two printed F and p pairs do not match each other at any sample size: pain-threshold group×time (F = 4.550, p = 0.001; that F gives p of roughly 0.01–0.04) and left-rotation group (F = 0.496, p = 0.186). The paper explains none of this.
Research review

Source-linked critical reading

randomized trial

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, discussion and references. The article has no figures, lists no supplementary material and has no funding or conflict-of-interest statement.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Prospective randomized experimental/control study with 30 inpatients, 15 per group. No sequence-generation, concealment or masking procedure is described.

Participants and setting

Hospital patients with posterior neck/shoulder pain and trapezius myofascial pain diagnosed on examination in 2011; 22 men and 8 women. Mean age was 40.86 in ESWT and 45.00 in control.

Treatment

EvoTron RFL0300 electrohydraulic low-energy ESWT, 1,500 shocks per session, 0.10 mJ/mm² and 240 shocks/minute; three weekly sessions (4,500 total shocks), targeting twitch/referred-pain sites.

Comparison

Trigger-point injections once weekly for three weeks plus TENS 20 minutes/day, five times weekly for three weeks. Injection drug and dose are not reported sufficiently for replication.

Outcomes and timing

Algometric pain threshold, VAS, McGill pain questionnaire, pain rating scale, neck motion, Roles/Maudsley and trigger-point response. Assessments were before treatment, one week after first session and one week after third session.

What the results show

Final VAS was 1.86±0.69 vs 2.80±0.84; threshold 12.57±0.72 vs 9.60±2.19 lb/cm² (ESWT/control). Group effects were p=.010 and .045, but VAS group×time was not significant (.162), whereas threshold interaction was printed as .001 (its F of 4.550 implies roughly .01–.04). McGill and pain-rating group effects were null (.816/.644); McGill interaction was .031. Total neck motion and global-response comparisons were not significant.

Harms

The paper discusses expected safety of low-energy ESWT but does not provide systematic event counts for this trial. Absence of a harm table is not evidence of zero adverse events.

Limits and disclosures

Hospital sample and brief observation, unclear allocation safeguards, multiple outcomes and incomplete comparator details. The distinction between group main effect and interaction is essential: authors overinterpret VAS superiority despite a null interaction. No dedicated funding/conflict statement was found in the supplied article. The printed continuous results are arithmetically consistent with about 12 analysed patients (7 ESWT, 5 control) rather than 30, which the paper does not explain.

Application to care

Findings concern hospitalized trapezius-pain patients and this low-energy protocol; they do not establish durable recovery, an optimal dose, or equivalence to injections/TENS.

What remains to be tested

Concealed randomized trials should prespecify a primary contrast, quantify harms, standardize injection/TENS and follow patients beyond the immediate course.

THE ORIGINAL SOURCE

Read the original article.

The Effect of Extracorporeal Shock Wave Therapy on Myofascial Pain Syndrome

Jeon JH, Jung YJ, Lee JY, Choi JS, Mun JH, Park WY, Seo CH, Jang KU. · Ann Rehabil Med · 2012

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →